PET-directed combined modality therapy for gastroesophageal junction cancer: Results of the multicentre prospective MEMORI trial of the German Cancer Consortium (DKTK).

BACKGROUND: Positron emission tomography (PET) may differentiate responding and non-responding tumours early in the treatment of locally advanced gastroesophageal junction adenocarcinomas. Early PET non-responders (P-NR) after induction CTX might benefit from changing to chemoradiation (CRT). METHODS: Patients underwent baseline 18F-FDG PET followed by 1 cycle of CTX. PET was repeated at day 14-21 and responders (P-R), defined as ≥35% decrease in SUVmean from baseline, continued with CTX. P-NR switched to CRT (CROSS). Patients underwent surgery 4-6 weeks post-CTX/CRT. The primary objective was an improvement in R0 resection rates in P-NR above a proportion of 70%. RESULTS: In total, 160 patients with resectable gastroesophageal junction adenocarcinomas were prospectively investigated by PET scanning. Eighty-five patients (53%) were excluded. Seventy-five eligible patients were enrolled in the study. Based on PET criteria, 50 (67.6%)/24 (32.4%) were P-R and P-NR, respectively. Resection was performed on 46 responders, including one patient who withdrew the ICF, and 22 non-responders (per-protocol population). R0 resection rates were 95.6% (43/45) for P-R and 86.4% (19/22) for P-NR. No treatment related deaths occurred. With a median follow-up time of 24.5 months, estimated 18 months DFS was 75.4%/64.2% for P-R/P-NR, respectively. The estimated 18 months OS was 95.5% for P-R and 68.2% for P-NR. CONCLUSION: The primary endpoint of the study to increase the R0 resection rate in metabolic NR was not met. PET response after induction CTX is prognostic for outcome with a prolonged OS and DFS in PET responders. TRIAL REGISTRATION: NCT00002014-000860-16.      «

BACKGROUND: Positron emission tomography (PET) may differentiate responding and non-responding tumours early in the treatment of locally advanced gastroesophageal junction adenocarcinomas. Early PET non-responders (P-NR) after induction CTX might benefit from changing to chemoradiation (CRT). METHODS: Patients underwent baseline 18F-FDG PET followed by 1 cycle of CTX. PET was repeated at day 14-21 and responders (P-R), defined as ≥35% decrease in SUVmean from baseline, continued with CTX. P-NR s...     »

591; Departments; Institut für Allgemeine Pathologie und Pathologische Anatomie (Dr. Mogler komm.); Institut für KI und Informatik in der Medizin (Prof. Rückert); Klinik und Poliklinik für Chirurgie (Prof. Friess); Klinik und Poliklinik für Innere Medizin II, Gastroenterologie (Prof. Schmid); Klinik und Poliklinik für Innere Medizin III, Hämatologie und Onkologie (Prof. Bassermann); Klinik und Poliklinik für Nuklearmedizin (Prof. Weber); Klinik und Poliklinik für RadioOnkologie und Strahlentherapie (Prof. Combs); Lehrstuhl für Medizinische Informatik (Prof. Boeker)     «

591; Departments; Institut für Allgemeine Pathologie und Pathologische Anatomie (Dr. Mogler komm.); Institut für KI und Informatik in der Medizin (Prof. Rückert); Klinik und Poliklinik für Chirurgie (Prof. Friess); Klinik und Poliklinik für Innere Medizin II, Gastroenterologie (Prof. Schmid); Klinik und Poliklinik für Innere Medizin III, Hämatologie und Onkologie (Prof. Bassermann); Klinik und Poliklinik für Nuklearmedizin (Prof. Weber); Klinik und Poliklinik für RadioOnkologie und Strahlenthera...     »